Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Antiplaque comments deadline

This article was originally published in The Tan Sheet

Executive Summary

Extension of deadline for comments on OTC antigingivitis/antiplaque advance notice of proposed rulemaking requested by CHPA, CTFA in July 15 joint petition to FDA. An additional 90 days to Nov. 25, instead of Aug. 25, would allow industry to prepare material addressing FDA's decision to classify several active ingredients as Category III (insufficient data), rather than Category I (safe and effective), the groups state. CHPA, CTFA also request 90-day delay of the reply comment period, arguing industry needs time to answer agency's call for statistical protocol and efficacy data on certain combination products before tentative final monograph is published. ANPR was released May 29 (1"The Tan Sheet" June 2, 2003, p. 3)...

You may also be interested in...



Antiplaque comment deadline

Comments on advance notice of proposed rulemaking for OTC Antigingivitis/Antiplaque Drug Products will be accepted until Nov. 25, FDA says in Federal Register notice scheduled for appearance Aug. 25. Reply comment period has been extended to Feb. 23, 2004. CHPA, CTFA jointly requested the extension to review data on ingredients the agency has proposed classifying as Category III in a July 15 petition (1"The Tan Sheet" July 28, 2003, In Brief)...

Antigingivitis/Antiplaque Combination With Other Actives Excluded In ANPR

FDA's advance notice of proposed rulemaking for OTC antigingivitis/antiplaque products excludes the combination of antigingivitis/antiplaque ingredients with other oral health care ingredients. The 1notice was published in the May 29 Federal Register

Genfit Delays NASH Data While It Confers With US FDA On Methodology

Genfit will delay unblinding of data from its nearly complete Phase III study of elafibranor to get insight from the FDA on statistical methods in order to optimize its NDA.

Topics

UsernamePublicRestriction

Register

PS095728

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel